Diana Andrei

Diana Andrei

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2025 in Life
Verified
Journal Article
Open access
PDF file
AGAngelica Gherman
Angelica Gherman
DADiana Andrei
Diana Andrei
Calin PopoiuCalin Popoiu
Calin Popoiu
Emil Robert StoicescuEmil Robert Stoicescu
Emil Robert Stoicescu
CLCodrina Levai
Codrina Levai
VBVlad Bloanca
Vlad Bloanca
The COVID-19 pandemic accelerated the adoption of virtual multidisciplinary teams (MDTs), transforming healthcare delivery through telemedicine. This review examines the integration of telemedicine into multidisciplinary care across various medical specialties, highlighting its benefits and challenges. A comprehensive literature search was conducted across PubMed, Google Scholar, Scopus, and Web of Science, using keywords related to telemedicine and MDTs. Inclusion criteria focused on studies discussing telemedicine implementation in multidisciplinary care, as well as its effectiveness and impact on patient outcomes, while non-English studies, single-case reports, and articles lacking explicit discussions on MDT integration were excluded. Data extraction covered telemedicine platforms, specialties involved, patient satisfaction, and clinical outcomes. Our findings suggest that virtual MDTs enhance efficiency, accessibility, and patient satisfaction, particularly in remote and underserved areas. However, challenges, such as technological barriers, disparities in digital access, and maintaining effective team communication, persist. Despite these limitations, telemedicine has demonstrated significant potential in improving diagnostic accuracy and treatment coordination. Future efforts should focus on optimizing infrastructure, digital training for healthcare providers, and regulatory frameworks to guarantee long-term sustainability.

20 March 2025 in Life
Verified
Journal Article
Open access
PDF file
DADiana Andrei
Diana Andrei
AMAlexandra Laura Mederle
Alexandra Laura Mederle
LGLaura Andreea Ghenciu
Laura Andreea Ghenciu
CBClaudia Borza
Claudia Borza
AFAlexandra Corina Faur
Alexandra Corina Faur
Traumatic brain injury (TBI) represents a significant public health issue, causing long-term disabilities and imposing considerable socioeconomic and healthcare challenges. While advancements in acute care have improved survival rates, the demand for effective neurorehabilitation is increasing. This narrative review explores the evidence on neurorehabilitation strategies for TBI, focusing on interventions targeting cognitive, motor, and psychological recovery. A total of 32 studies were included and categorized into six approaches: non-invasive brain stimulation, virtual reality (VR), computer-based training, telerehabilitation, robot-assisted therapy (RAT), and mixed approaches. Non-invasive brain stimulation techniques, such as transcranial direct current stimulation (tDCS) and repetitive transcranial magnetic stimulation (rTMS), showed variable effectiveness in improving cognitive outcomes. VR-based therapies enhanced attention and executive functions, while RAT, such as Lokomat and exoskeletons, improved gait symmetry and functional mobility. Computer-assisted programs demonstrated benefits in rehabilitating social cognition and executive functions. Telerehabilitation and telephone-based treatments provided short-term gains but lacked sustained effects. Overall, cognitive improvements were better described and represented, while several motor improvements lacked consistency. Despite the promising results, significant gaps remain, including heterogeneity in methodologies, small sample sizes, and limited long-term outcome data.

30 June 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
LGLaura Andreea Ghenciu
Laura Andreea Ghenciu
DADiana Andrei
Diana Andrei
CBClaudia Borza
Claudia Borza
RSRoxana Stoicescu
Roxana Stoicescu
Emil Robert StoicescuEmil Robert Stoicescu
Emil Robert Stoicescu
OHOvidiu Hategan
Ovidiu Hategan
Background/Objectives: Rho-associated coiled-coil-containing protein kinase inhibitors (ROCKis) have now become known as modulators of corneal endothelial wound repair and cell survival. However, evidence remains fragmented across laboratory and clinical reports. We performed a systematic review to synthesize preclinical and clinical data on ROCKis in corneal disease, assess their efficacy and safety, and identify research gaps. Methods: We searched PubMed, Web of Science, Scopus, and Google Scholar (until May 2025) for English-language original studies evaluating ROCKis in corneal models or patients. Inclusion criteria encompassed in vitro, ex vivo, in vivo, and clinical trials reporting functional outcomes (endothelial cell density, wound closure, visual acuity). Results: Thirty-one studies met criteria: 14 preclinical studies and 17 clinical studies. Preclinical models (rabbit, porcine, human explants) uniformly showed ROCKis (Y-27632, Ripasudil, Netarsudil, H-1152) accelerate corneal endothelial cell proliferation, migration, and restoration of a hexagonal monolayer with improved barrier and pump function over days to weeks. In 17 clinical investigations, topical Ripasudil or Netarsudil and cultured cell injections achieved significant corneal thinning, endothelial cell density and central corneal thickness changes, and visual acuity improvements (≥2 lines) with minimal adverse events. Overall bias was moderate in non-randomized studies and low in the RCTs. Conclusions: ROCKis demonstrate consistent pro-regenerative effects on corneal endothelium in multiple models and show promising clinical efficacy in Fuchs endothelial dystrophy and pseudophakic endothelial failure. Future work should explore novel delivery systems and larger controlled trials to optimize dosing, safety, and long-term outcomes.

20 June 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
ARAndrada-Iasmina Roşu
Andrada-Iasmina Roşu
DADiana Andrei
Diana Andrei
LGLaura Andreea Ghenciu
Laura Andreea Ghenciu
SBSorin Lucian Lucian Bolintineanu
Sorin Lucian Lucian Bolintineanu
Hydrocephalus is a complex neurological condition marked by abnormal cerebrospinal fluid (CSF) accumulation, often leading to elevated intracranial pressure and structural brain damage. Despite advances in surgical treatment, diagnostic precision and prognosis remain challenging, especially in idiopathic normal pressure hydrocephalus (iNPH). This narrative review aims to synthesize the current knowledge regarding molecular and neuroimaging biomarkers that hold diagnostic, prognostic, and therapeutic significance in hydrocephalus. A comprehensive literature search was conducted across PubMed, Scopus, Web of Science, and Google Scholar. The inclusion criteria encompassed peer-reviewed studies involving congenital or acquired hydrocephalus and reporting on mechanistic, diagnostic, or monitoring biomarkers. Both established and emerging biomarkers were included, and preclinical findings were considered when translational relevance was apparent. The review highlights a broad spectrum of molecular markers including aquaporins, vascular endothelial growth factor, neurofilaments, glial fibrillary acidic protein, matrix metalloproteinases, and neuroinflammatory markers. The genetic markers associated with ciliogenesis also show promise in subtyping disease. Parallel to molecular advances, neuroimaging techniques, ranging from classic markers like Evans’ index to advanced modalities such as diffusion tensor imaging (DTI), arterial spin labeling (ASL), and glymphatic MRI, provide functional perspectives on hydrocephalus diagnosis and management, while artificial intelligence may further enhance diagnostic algorithms. Molecular and imaging markers could not only increase diagnostic confidence, but also provide information on disease causes and progression. As research progresses, merging various methodologies may result in more accurate diagnoses.

13 February 2025 in Life
Verified
Journal Article
Open access
PDF file
AIAlexandra Magdalena Ioana
Alexandra Magdalena Ioana
DADiana Andrei
Diana Andrei
DIDaniela Iacob
Daniela Iacob
SBSorin Lucian Lucian Bolintineanu
Sorin Lucian Lucian Bolintineanu
Thyroid-associated ophthalmopathy (TAO), or Graves’ orbitopathy (GO), is a complex autoimmune disorder affecting orbital tissues, often leading to vision-threatening complications such as dysthyroid optic neuropathy (DON). In this systematic review, conducted following PRISMA guidelines, 22 studies were evaluated to investigate the role of optical coherence tomography (OCT) in assessing retinal and choroidal changes in TAO. Parameters such as the retinal nerve fiber layer (RNFL), ganglion cell complex (GCC), ganglion cell layer (GCL), and choroidal thickness were analyzed. RNFL changes varied by disease severity, with significant thinning in DON due to nerve fiber loss and thickening in early DON due to optic disk edema. Subfoveal choroidal thickness (SFCT) was consistently higher in active TAO, correlating positively with the clinical activity score (CAS) and proptosis, suggesting its role as a marker of disease activity. Subgroup analysis revealed that spectral-domain OCT (SD-OCT) was the most sensitive for detecting retinal changes. The findings highlight the effectiveness of OCT in detecting minor retinal and choroidal alterations in TAO. However, the variability of study designs, as well as the lack of longitudinal data, limits the ability to draw broad conclusions. Further standardized, long-term investigations are required to properly understand OCT’s diagnostic and prognostic value in TAO.

22 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
AMAlexandra Laura Mederle
Alexandra Laura Mederle
DADiana Andrei
Diana Andrei
LGLaura Andreea Ghenciu
Laura Andreea Ghenciu
Emil Robert StoicescuEmil Robert Stoicescu
Emil Robert Stoicescu
RSRoxana Stoicescu
Roxana Stoicescu
OHOvidiu Hategan
Ovidiu Hategan
Background/Objectives: Dry eye disease (DED) is a prevalent, complex disorder with a major impact on patients’ quality of life. While artificial tears (AT) are still the first-line treatment, their effectiveness is often limited in moderate-to-severe cases. Autologous serum (AS) and platelet-rich plasma (PRP) are now recognized as viable biologic treatments due to their regenerative and anti-inflammatory characteristics. This systematic review and meta-analysis sought to assess and compare the clinical efficacy of PRP, AS, and AT in the treatment of DED, with a focus on comparative studies. Methods: A comprehensive search of PubMed, Scopus, and Google Scholar was conducted until June 2025 for studies directly comparing PRP, AS, and AT. Eligible trials included patients with DED who reported results such as the Schirmer test, tear break-up time (TBUT), and Ocular Surface Disease Index (OSDI). The risk of bias was calculated using ROB 2 for randomized trials and ROBINS-I for non-randomized studies. Meta-analyses were carried out using standardized mean differences (SMDs) and 95% confidence intervals (CIs). Results: Seventeen studies were included in the systematic review. Both PRP and AS demonstrated greater improvements in OSDI, TBUT, and Schirmer test scores compared to AT. PRP showed a trend toward better outcomes than AS, especially in studies using injectable PRP. However, substantial heterogeneity and methodological variability were noted. Conclusions: Comparative research suggests that PRP and AS are more effective than AT in treating DED. Direct comparisons of PRP and AS yield varied results, with the route of delivery impacting outcomes. Given the heterogeneity of current protocols, further standardized, long-term trials are required to confirm the optimal delivery method and ensure safety.